Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Urology
|
March 6, 2012
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109
Ryan K Berglund, Catherine M Tangen, Isaac J Powell, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
The Prostate
|
June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
European Urology
|
May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Andrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
October 22, 2025
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Urology
|
March 6, 2012
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109
Ryan K Berglund, Catherine M Tangen, Isaac J Powell, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
The Prostate
|
June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
European Urology
|
May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Andrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
JAMA Network Open
|
May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial
Arun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
The Journal of Urology
|
December 9, 2025
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Neal D Shore, Martin Gleave, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
October 22, 2025
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Neal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, et al.
The New England Journal of Medicine
|
October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Stephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Page
of 9